RLAY Q3 2024 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$96M

Net Income

-$88M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$75M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$930M

Total Liabilities

$91M

Stockholders' Equity

$839M

Cash & Equivalents

$152M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$25M	-100.0%
Gross Profit	$0	-$56M	+100.0%
Operating Income	-$96M	-$74M	-31.0%
Net Income	-$88M	-$66M	-34.0%